In 2026, the federal quota order sets the maximum total amount of psilocybin and psilocyn that can be produced domestically for permitted uses, and that cap shapes how you plan timelines, enrollment and manufacturing slots for clinical trials.
What the 2026 quota order covers
The quota order sets annual aggregate production quotas for controlled substances and annual needs for certain listed chemicals. The 2026 final order is effective January 5, 2026.
Aggregate production quotas are the ceiling for how much of a drug class may be produced in the United States in a calendar year for medical, scientific, research and industrial needs, export needs and reserve stocks. Imports are handled through separate approvals and the aggregate quota table does not automatically cover every import scenario, so your supply plan should treat domestic production and imports as distinct tracks.
For psilocybin research, the key numbers in the 2026 order are the aggregate caps for the basic classes psilocybin and psilocyn, expressed in grams. The 2026 order sets psilocybin at 50,000 grams and psilocyn at 80,000 grams. The order also notes that these two caps were set higher than the proposed levels after a request during the public process.
The order is an aggregate ceiling, not a purchase authorization. The quota system works through separate registrations and separate quota applications for each basic class. Manufacturers apply for individual manufacturing quotas, importers and other registrants apply for procurement quotas and the quota administrator can adjust quotas during the year when the record supports it.
The quota order also sits inside broader federal scheduling. Psilocybin and psilocyn are listed in Schedule I under federal regulation, which is why quotas, storage controls and recordkeeping requirements apply in research settings that handle them.
Why quotas affect psilocybin assisted therapy research
Quotas affect research in a practical way because they set a shared annual ceiling for every licensed activity that depends on bulk substance, including clinical development, nonclinical work, analytical standards and retained samples. Even when your own trial uses relatively small milligram quantities per participant, you still depend on a supply chain that has capacity limits, release testing steps and reserved inventory that sits outside the dosing calculation.
You also work inside a calendar. Aggregate quotas are set for a given year and individual quotas are allocated inside that window. If demand rises after allocations are made, the quota system can become a scheduling constraint even if the total grams look large on paper.
Study capacity and lead times
Your study capacity is tied to more than the number of doses you plan to administer. Supply planning usually includes active ingredient for the trial product, extra quantity for formulation work, quality testing, stability pulls and retained samples, plus any loss tied to processing and handling. Those additional uses are common in clinical development and they add up across multiple studies running in parallel.
Lead times also stack. You can face delays at several points that are independent of the chemistry. You may wait for registration changes, quota allocations, production slots, analytical release and final packaging. When you run a multi-site trial, you also deal with scheduling across sites so that drug product arrives with enough shelf life and with documentation that matches each site’s storage and accountability plan.
A simple way to think about the 2026 quota numbers is as a hard upper bound. They do not tell you how much will be available to your team at a given time. Availability depends on how much of the aggregate cap is already committed across all approved work, how quickly quotas are allocated and how quickly material moves through release. The quota order itself acknowledges that quotas can be adjusted if the record supports it, which is helpful, but adjustment still takes time and paperwork.
Materials covered and materials not covered
The quota system is based on basic drug classes, so psilocybin and psilocyn are treated as separate line items with separate caps. That distinction can show up in real work. Your protocol might dose psilocybin while your bioanalytical program measures psilocyn in plasma, and your lab might need reference standards for both compounds.
The quota order covers how much of each basic class may be produced for approved uses. It does not cover many items that still drive timelines and budgets, such as excipients, capsules, packaging components, validated cold chain materials, stability chambers and analytical consumables. It also does not remove the need for site-level storage capacity, chain-of-custody controls and staff training that match the regulated status of the substance.
What research teams can do next
You can take a few steps that make supply planning clearer without turning it into a procedural playbook. The goal is to align your scientific plan with the calendar of quotas and the operational reality of manufacturing and release.
Demand forecasting basics
Start with your protocol and convert it into a total substance requirement. You can do this in a way that stays practical and audit-ready.
- Participant count and expected completion rate
- Dosing sessions per participant and dose strength per session
- Overages for manufacturing losses, formulation work and retained samples
- Quality testing needs, including reference standards and repeat testing
- Stability and shelf life needs tied to your visit schedule
You can then map those quantities to when you need them. A trial that enrolls in waves often needs staggered delivery and staggered release testing. That timeline becomes more important as you move to larger trials, add sites or plan back-to-back studies.
Once you have a forecast, you can compare it to the quota calendar. Quota requests are generally filed months before the year in question, and the quota application guidance lists standard deadlines for different kinds of quota requests. If you miss those cycles, you can still pursue adjustments, but you should expect more delay and more back and forth.
High-level approvals and documentation map
Supply is closely tied to documentation. In regulated research, delays often come from a missing approval or a mismatch between what is permitted and what is being requested.
At a high level, you usually need a clear chain that connects your study plan to your controlled substance permissions. That can include ethics review approval for the protocol, registrations that allow the relevant activities, secure storage plans at each site and the quota paperwork that covers production, procurement or import. The quota guidance notes that applications are separate for each basic class and that different registrant types apply depending on the activity.
You also benefit from a clean version history. When your protocol changes, supply plans and documentation need to stay aligned. A mid-study dose change or a new arm can trigger new forecasting, new packaging needs and new quota requests.
Common blockers that slow sourcing
A few blockers show up repeatedly across research programs.
One blocker is misalignment between the planned analyte and the requested substance. You may be planning psilocybin dosing but requesting quantities that are tied to psilocyn analytical work, or you may need both but only request one basic class.
Another blocker is late recognition of the non-dosing uses of supply. Stability programs, retained samples and repeat testing can consume more material than teams expect, especially when methods change or when batches need rework.
A third blocker is timing. Quotas are annual. If you start sourcing late in the year, you can run into allocation limits for that year or production schedules that are already full. Even when the aggregate quota looks sufficient, individual quotas and production slots can be the true bottleneck.
Documentation gaps also slow timelines. Controlled storage plans, shipping documentation, site accountability logs and version control across study documents can create delays when they are inconsistent across sites.
Finally, chemical handling realities can create rework. Psilocybin and psilocyn are distinct compounds with different behavior in samples. Your team may need both standards, and you may need to account for how material is stored, sampled and transported so the work you do in the lab stays consistent over time.
Quick checklist for planning supply
Use this checklist when you are aligning your clinical trial plan to 2026 supply constraints.
- Confirm which basic classes you need for dosing, analytics and standards
- Pull the 2026 aggregate caps for those classes and note that psilocybin is 50,000 grams and psilocyn is 80,000 grams
- Build a total quantity forecast that includes overages, testing and retained samples
- Map your forecast to calendar milestones for quota requests and expected allocations
- Align storage capacity and accountability plans at every site to the regulated status of the substance
- Plan release testing and packaging lead times before enrollment ramps
- Track protocol changes and update supply and documentation at the same time
We are Rose Hill Life Sciences, a psychedelic research organization specializing in the production and research of Psilocybe cubensis, operating at the intersection of science and therapeutic integration, and we are based in Massachusetts.
